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Increased glomerular filtration rate after withdrawal of long-term
antihypertensive treatment in diabetic nephropathy
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and HANS-HENRIK PARVING
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Increased glomerular filtration rate after withdrawal of long-term
antihypertensive treatment in diabetic nephropathy. Initiation of antihy-
pertensive treatment (AHT) in hypertensive insulin-dependent diabetic(IDDM) patients with diabetic nephropathy (DN) induces a faster initial
(0 to 6 months) and a slower subsequent (6 months to end of observation)
decline in GFR [1GFR (ml/min/month) approximately 1.5 vs. 0.35].
Whether this initial phenomenon is reversible (hemodynamic) or irrevers-
ible (structural damage) after prolonged Al-IT is not known. To elucidate
these mechanisms we investigated 42 hypertensive IDDM patients (16F/
26M, age 40 7 years, mean so) with DN receiving ART (angiotensin
converting enzyme inhibition, N = 30) for 6 (2 to 15) years [median
(range)]. GFR (ml/minhl.73 m2), arterial blood pressure (BP, mm Hg) and
albuminuria (mg/24 hr) were measured the last day on AHT and one
month after withdrawal of ART. The measured variables were all
significantly elevated after withdrawal of ART: GFR [mean(sEM)1 from
76(4) to 81(4) (P < 0.0001), BP [mean(5EM)] from 140/82 (2/1) to 151/89
(2/1) (P < 0.0005) and albuminuria [geometric mean(antilog SCM)] from
704 (1.2) to 1122 (1.2) (P < 0.0001). A correlation between relative rise in
systolic blood pressure (Sys%) and relative change in GFR (GFR%)
was found (r = 0.44, P < 0.005). Our results render some support of the
hypothesis that the faster initial decline in GFR is due to a functional
(hemodynamic) effect of AHT, which does not attenuate over time, while
the subsequent slower decline reflects the beneficial effect on progression
of diabetic nephropathy.
Nearly 40% of all insulin-dependent diabetic (IDDM) patients
develop persistent albuminuria, a relentless decline in glomerular
filtration rate (GFR), and raised arterial blood pressure (BP), that
is, the clinical syndrome of diabetic nephropathy [1]. Elevated BP
accelerates the progression of diabetic nephropathy [2—4] and
effective antihypertensive treatment (AHT), in particular with
angiotensin converting enzyme inhibitors (ACE!), reduces albu-
minuria and the rate of decline in GFR in this condition [5—9].
Initiation of ART induces a faster initial (0 to 6 months) and
slower subsequent (6 months to end of observation) decline in
GFR [GFR (mi/mm/month) approximately 1.5 vs. 0.35] in
hypertensive IDDM and non-insulin dependent diabetic
(NIDDM) patients with incipient or overt diabetic nephropathy
[7, 8, 10]. The same phenomenon has been recorded in the
"Modification of diet in renal disease" (MDRD) study dealing
with non-diabetic nephropathies [11—13]. Whether this initial
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faster decline in GFR is caused by a functional (hemodynamic)
effect, which will not attenuate over time, or if it reflects an
irreversible phenomenon (structural damage) is unknown. These
mechanisms must be revealed in order to make a valid interpre-
tation of the potential beneficial effect of long-term ART on the
progression of diabetic and non-diabetic nephropathies.
Our study aimed to elucidate this concept by recording the
effect of withdrawing ART on BP, GFR and albuminuria in
IDDM patients with diabetic nephropathy receiving long-term
ART.
Methods
Patients
Forty-two (16 females/26 males) consecutive hypertensive
IDDM patients with diabetic nephropathy, who accepted to
participate in a double blinded, randomized trial comparing
lisinopril and nisoldipin (cc) were studied before the start of this
trial. Diabetic nephropathy was diagnosed clinically if the follow-
ing criteria were fulfilled: persistent albuminuria above 300 mg/24
hr, presence of diabetic retinopathy and no clinical or laboratory
evidence of other kidney or renal tract disease, other than diabetic
glomerulosclerosis [141. All patients had been insulin-dependent
from the time of diagnosis and all were receiving at least two daily
injections of insulin. Diabetic retinopathy was evaluated by fundus
photography after pupillary dilatation and graded: none, simplex
or proliferative. All patients had received ART for at least two
years. Thirty patients were treated with an ACE! either alone (N
= 5) or in combination with diuretics (N = 24) and/or a calcium
channel blocker (N = 8) and/or a selective /3-blocker (N = 3)
and/or an a-blocker (N 2). Twelve patients were treated with
diuretics alone (N 5) or in combination with either a calcium
channel blocker (N = 5) and/or a selective /3-blocker (N = 4)
and/or an a-blocker (N = 2). Patients were excluded if they had a
previous history of stroke/TIA, congestive heart failure (NYHA
III-IV), myocardial infarction or coronary bypass surgery within
the last three months and/or unstable angina. All patients were
between 18 and 55 years of age. Characteristics of the 42
hypertensive IDDM patients with diabetic nephropathy are given
in Table 1. The study was approved by the Regional Ethics
Committee.
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Table 1. Clinical characteristics of 42 hypertensive IDDM patients with
diabetic nephropathy receiving long-term antihypertensive treatment
(> 2 years)
Sex (F/M) 16/26
Age (years)a 40 (7)
Duration of diabetes (years)a 26 (6)
HbA1C (%) 9.0 (1.3)
Insulin dosage (U/kg/day)a
Duration of antihypertensive treatment (years)''
0.63 (0.14)
6 (2—15)
Duration of persistent albuminuria (years)' 6 (2—19)
Retinopathy (simplex/proliferative) 14/28
a Mean (SD)
b Median (range)
Procedure
On the last day of AHT (baseline) and four weeks after
withdrawal of all antihypertensive drugs BP, GFR and albumin-
uria were determined. All patients received placebo in the four
week period.
All investigations were performed with the patients in the
supine position between 8 a.m and 1 p.m. The investigations were
started in the morning after an overnight fast. Patients had
breakfast and morning insulin 30 minutes after the start of the
GFR investigation and drank approximately 200 ml of tap water
per hour during the investigation period. GFR was measured after
a single intravenous injection of 3.7 MBq Na51Cr-labeled edetic
acid (51Cr-EDTA) at 8 a.m., by determining the radioactivity in
venous blood samples 180, 200, 220 and 240 minutes after the
injection [15, 16]. The small underestimation (10%) of 51Cr-
EDTA clearance versus clearance of inulin was corrected for by
multiplying the EDTA clearance by 1.10 [15]. The results were
standardized for 1.73 m2 body surface area. The mean coefficient
of variation in GFR is 4% in our laboratory.
In 34 patients linear regression analysis (least squares method)
was used to estimate the rate of decline in GFR during the AHT
period previous to the present investigation by using all determi-
nations of GFR (range: 2 to 9) over a period of time of 31(13 to
121) months [median(range)]. The rate of decline in GFR could
not be determined in the remaining eight patients, because of
insufficient numbers of GFR measurements or a short observation
period (less than 12 months).
BP was measured on the right arm after at least 10 minutes rest
in the supine position with a Hawksley random zero sphygmoma-
nometer, using appropriate cuff sizes [25 X 12 cm (upper arm
circumference  35 cm) and 30 x 15 cm (upper arm circumfer-
ence > 35 cm)]. Diastolic blood pressure was recorded at the
disappearance of Korotkoff sounds (phase V). The individual BP
level was determined as the mean of at least two measurements
performed during the GFR determination. Albuminuria was
determined by using an enzyme linked immunoadsorbent assay
[17]. From venous blood samples hemoglobin A1 (HbA1) was
measured by high performance liquid chromatography (DIAMAT
analyzer, BIO-RAD, CA, USA). The normal range of HbA1C in
our laboratory is 4.1 to 6.4%.
Statistical analysis
Normally distributed data are expressed as mean and standard
deviation (SD) or standard error of the mean (sEM). Duration of
persistent albuminuria and duration of AHT are expressed as
median and range owing to their skewed distribution. Values for
Table 2. Arterial blood pressure (BP), mean arterial blood pressure
(MAP), GFR and albuminuria in 42 hypertensive IDDM patients with
diabetic nephropathy, at baseline (last day of long-term antihypertensive
treatment) and four weeks later without any antihypertensive treatment
Baseline 4 weeks P
BP (mm Hg)a 140/82 (2/1) 151/89 (2/1) <0.0005
MAP (mm Hg)a
GFR (ml/min/1.73 m2)a
Albuminuria (mg/24 hr)'
101 (1)
76 (4)
704 (1.2)
109 (1)
81(4)
1122 (1.2)
<0.0001
<0.0001
<0.0001
a Mean (SEM)
b Geometric mean (antilog SaM)
albuminuria were logarythmically transformed before analysis and
expressed as geometric mean and antilog SEM, because of their
positively skewed distribution. Paired Student's t-test was used to
compare BP, GFR and albuminuria at baseline and four weeks
after withdrawal of AHT in the whole group of patients. Unpaired
Student's f-test was used to compare ACEI and non-ACE! treated
patients, relating to baseline values of MAP, GFR and albumin-
uria and changes in mean arterial blood pressure (MAP), GFR
and albuminuria from baseline (visit 0) to four weeks after (visit 4)
withdrawal of AHT. Change in albuminuria is expressed as the
mean relative change (%)with 95% confidence interval, from visit
0 to visit 4. Linear regression analysis (least squares method) was
used to analyze data for correlations. All calculations were made
using Statgraphics (STSC, Rockville, MD, USA). A P value of <
0.05 was considered significant (two-tailed).
Results
BP, GFR and albuminuria were all significantly elevated after
withdrawal of long-term AHT (Table 2). Figures 1, 2 and 3
illustrate the individual changes in mean arterial blood pressure
(MAP), GFR and albuminuria, from baseline (on AHT) to the
visit four weeks after withdrawal of all antihypertensive drugs,
respectively.
Thirty-two patients had an increase in MAP (ACEI, N = 22),
while eight had a drop in MAP (ACE!, N = 6). On average the
increase amounted to 8 (1) mm Hg (Fig. 1).
GFR rose in 32 patients (ACE!, N = 24), while 8 patients
(ACE!, N = 5) had a slight reduction in GFR. The mean increase
was 5(1) ml/min/1.73 m2 (Fig. 2). The increase in GFR was not
related to the baseline GFR level.
Albuminuria rose in 34 patients (ACEI, N = 26) and decreased
in seven patients (ACE!, N = 4) after withdrawal of AHT (Fig. 3).
Our study revealed no significant differences in the change of
MAP, GFR and albuminuria after four weeks withdrawal of
ACEI (N = 30) compared to non-ACEI (N = 12) in hypertensive
IDDM patients suffering from diabetic nephropathy. However,
the rise in albuminuria tended to be higher in the ACEI versus the
non-ACEI group, 71% versus 34%, but the numbers were small
(Table 3).
Linear regression analysis revealed a significant correlation
between relative change in systolic blood pressure (Sys%) and
relative change in GFR (AGFR%; r = 0,44, P < 0.005); (Fig. 4).
Compared to the whole group of patients there was a slightly
better correlation between Sys% and LGFR% in patients
receiving ACE! (r = 0.50, P < 0.005). Furthermore, a significant
correlation between relative change in MAP (MAP%) and
LGFR% (r = 0.34, P < 0.05) was also found. We found no
Time, weeks
Fig. 1. Mean arterial blood pressure (MAP) at baseline [last day of long-
term antihypertensive treatment (AHT)] and four weeks after withdrawal of
long-term AHT, in 42 hypertensive IDDM patients with nephropathy. Thirty-
two patients had a rise in MAP and eight patients dropped in MAP. A.
Average MAP (101 mm Hg) at baseline, and B. average MAP (109 mm
Hg) four weeks after withdrawal of AHT (P < 0.0001).
correlation between duration of antihypertensive treatment and
absolute change in GFR (r = 0.10, P > 0.5; Fig. 5), and no
correlation between the relative change in systolic blood pressure
and relative change in albuminuria (P> 0.1), or between relative
change in GFR and relative change in albuminuria (P> 0.2).
The rate of decline in GFR during the AHT period preceding
the present investigation was 3.5 (—8 to 27) ml/min/year [medi-
an(range)].
Discussion
Our prospective study shows that short-term withdrawal (one
month) of long-term antihypertensive treatment (years) induces a
rise in BP, GFR and albuminuria in hypertensive IDDM patients
suffering from diabetic nephropathy. It should be mentioned that
some variation in the response occurred, since 20 to 25% of the
patients had an unchanged or decrease in BP and/or GFR and/or
Time, weeks
Fig. 2. GFR at baseline [last day of long-term antihypertensive treatment
(AHT)] and four weeks after withdrawal of AHT, in 42 hypertensive IDDM
patients with diabetic nephropathy. Thirty-two patients had an increase in
GFR and eight patients had a decline in GFR. A. Mean GFR at baseline
(76 ml/min/1.73 m2), and B. mean GFR four weeks after withdrawal of
AHT (81 ml/min/1.73 m2; P < 0.0001).
albuminuria, respectively. Correlations between Sys% and
ZGFR% and between LMAP% and zGFR% were demon-
strated. No correlation was found between the absolute change in
GFR and duration of antihypertensive treatment, suggesting that
the capability to increase GFR after withdrawal of long-term
antihypertensive treatment does not attenuate over time. Finally
our study demonstrates that the yearly rate of decline in GFR (3.5
ml/min) during long-term antihypertensive treatment is low as
compared to approximately 12 ml/min/year, reflecting the natural
course of diabetic nephropathy [6, 18].
Recently, Apperloo et al [19] have demonstrated that the initial
decline in GFR induced by antihypertensive treatment can be
regained after short-term withdrawal of this treatment in 36
proteinuric non-diabetic patients (GFR > 30 ml/min/1.73 m2),
treated for 3.8 years with atenolol or enalapril in a double-blind
trial (code has still not been broken).
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Time, weeks
Fig. 3. Albuminuria at baseline [last day of long-term antihypertensive
treatment (AHT)J and four weeks after withdrawal of long-term AHT, in 42
hypertensive IDDM patients with diabetic nephropathy. Albuminuria rose in
34 patients and dropped in 7 patients. A. Geometric mean albuminuria
(704 mg124 hr) at baseline, and B. geometric mean albuminuria (1122
mg/24 hr) four weeks after withdrawal of AHT (log scale; P < 0.0001).
The effect of pharmacological blood pressure lowering and/or
reduction of dietary protein intake on the rate of decline in GFR
can best be fitted to a two-slope model, with a faster initial (during
the first 4 to 6 months) and a slower sustained (6 months to end
of observation) decline in GFR of approximately 1.5 and 0.35
mI/mm/month, respectively [7, 8, 101. This phenomenon has been
demonstrated in IDDM and NIDDM patients with incipient or
overt diabetic nephropathy and in non-diabetic nephropathies [7,
8, 10, 11]. The initial rapid loss of GFR may represent either a
destruction of nephrons (progression in renal disease), or it may
reflect a functional hemodynamic effect of low blood pressure
and/or low protein diet intervention without a loss of nephrons. In
case the first mentioned event takes place, then the initial drop in
GFR has to be accounted for, when evaluating the long-term
effect of intervention on progression of kidney disease. However,
if the initial steeper drop in GFR is hemodynamically induced
(reversible) then only the sustained effect on GFR, reflecting
progression of the renal disease, should be analyzed in long-term
intervention trials. Several recent studies lasting at least 2½ years
shows a beneficial effect of AHT and/or low protein diet in
diabetic and non-diabetic nephropathies, if and only if the sus-
tained effect on GFR is analyzed [5, 11, 20].
The MDRD study randomly assigned patients with moderate
renal insufficiency to a usual- or a low-protein diet and to a usual-
or a low-blood pressure group [11]. As compared with the
usual-protein group and the usual-blood pressure group, the
low-protein group and the low-blood pressure group had a more
rapid decline in GFR during the first four months after random-
ization and a slower decline thereafter. The effect of the dietary
intervention was similar in the two blood pressure groups, and the
effect of the blood pressure intervention was similar in the two
diet groups.
The initial drop in GFR after four months of AHT is about 6
ml/min in diabetic nephropathy and our study revealed a regain in
GFR of the same order of magnitude after one month of
withdrawal of AHT, which may suggest a reversible hemodynamic
effect. Unfortunately, we have no data prior to and shortly after
the initiation of antihypertensive treatment in our patients. Fur-
thermore, our study cannot rule out the possibility that the initial
hemodynamically-mediated decline in GFR had attenuated over
time and yet, the diabetic kidney, retained the ability to respond
to a relatively acute increase in BP with an increase in GFR.
The physiological determinants of GFR are: The ultrafiltration
coefficient (Kf), the transcapillary hydraulic pressure difference
(P) and the transcapillary oncotic pressure difference (i). We
have no direct information on these variables. However, we found
a correlation between Sys% and LGFR% and between LMAP%
and GFR%. Systemic blood pressure elevation is only of impor-
tance for the regulation of GFR if it is transmitted downstream to
the glomeruli, resulting in glomerular hypertension. This is likely
to occur since the autoregulation of GFR [or intraglomerular
hydraulic pressure (PGc)J, that is, the maintenance of relative
constancy of GFR (or P0) despite variations in mean arterial
blood pressure above 80 mm Hg [21—25], is impaired in diabetic
nephropathy [26]. A complete pressure-passive vasculature has
been found in 30% of the patients with diabetic nephropathy
(zXGFR% = MAP%) [26]. Impaired autoregulation of renal
blood flow (RBF) and GFR has also been found in experimental
models of non-diabetic nephropathies [27—29]. The renin-angio-
tensin system has been suggested to play a role in the autoregu-
lation of GFR [30]. However, angiotensin II antagonists failed to
interfere with renal autoregulation in the majority of studies
performed [31—33].
Inhibition of the angiotensin converting enzyme prevents the
action of angiotensin II on mesangial cells and the efferent
arteriole, thereby enhancing K and reducing the P0 irrespective
of the effect on systemic hypertension. Consequently withdrawal
of ACE inhibition should induce a reduction in Kf, offsetting the
enhancing effect of glomerular hypertension on GFR. The net
result of these opposing variables in our study was an increased
GFR. We have no information suggesting that conventional
antihypertensive drugs have specific effects on the above-men-
tioned determinants of GFR, but f3-blockers may reduce renal
blood flow. No difference in the rise of GFR after withdrawal of
ACEI and non-ACEI was found, but the numbers of patients
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Table 3. Changes in MAP, GFR and albuminuria after four weeks withdrawal of angiotensin converting enzyme inhibitors (ACEI) versus non-
ACEI in 42 hypertensive IDDM patients with diabetic nephropathy
Antihypertensive
m
MAYA
rn Hg mi/rn
GFR
in/1.73 m2 m
Albuminuria
g/24 hrb %C
Visit Visit Visit
treatment 0 4 0 4 0 4
ACE! (N = 30)
Non-ACE! (N = 12)
102 (2)
100 (3)
110 (2)
108 (2)
8 (2)
8 (2)
78 (5)
72 (6)
84 (5)
77 (5)
6 (1)
5 (2)
682 (1.2)
762 (1.3)
1166 (1.2)
1019 (1.3)
71(40 to 209)d
34 (—5 to 88)d
a Mean (sEM)b Geometric mean (antilog sEM)C Average relative change (%) from visit 0 to 4 with 95% confidence intervaldP = 0.21 compared to ACE!
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Fig. 4. Correlation between relative change in systolic blood pressure
(Sys%) and relative change in GFR (iGFR%) in 42 hypertensive IDDM
patients previously receiving long-term antihypertensive treatment (r = 0.44, P
<0.005).
Fig. 5. No correlation between duration of antihypertensive treatment and
absolute change in GFR (AGFR; r = 0.10, P > 0.5) was found.
studied were small, particularly in the non-ACE! group. Unfor-
tunately, we have no data on plasma oncotic pressure during and
after withdrawal of AHT, but we do not expect significant changes
in M9.
Antihypertensive treatment with ACE! or non-ACE! reduces
albuminuria in diabetic nephropathy [5—7, 18]. Given the same
systemic blood pressure level, ACE! are usually more potent than
non-ACE! in reducing albuminuria, suggesting a local effect on
PGC and/or a non-hemodynamic effect in the glomeruli. The rise
in albuminuria after stopping antihypertensive treatment was
nearly twice as high in the group treated with ACEI compared to
the non-ACEI treated group (Table 3).
The size and charge selectivity of the glomerular capillary
filtration barrier is impaired in patients with diabetic nephropathy
[34]. Antihypertensive treatment with an ACEI has been shown to
improve both size and charge selective properties [35]. Studies on
the effect of acute blood pressure reduction with clonidin suggest
that albuminuria in diabetic nephropathy is pressure dependent to
a large extent [26]. These findings propose that the rise in
albuminuria after withdrawal of antihypertensive treatment is
probably due to both hemo- and non-hemodynamic mechanisms.
Studies concerning the effect of withdrawal of long-term anti-
hypertensive treatment on BP, GFR and albuminuria in NIDDM
patients with diabetic nephropathy and on albuminuria in patients
with non-diabetic nephropathies are lacking.
In conclusion, our results render some support of the hypoth-
esis that the faster initial decline in GFR after initiating antihy-
pertensive treatment in hypertensive IDDM patients with diabetic
Hansen et al: Diabetic nephropathy and antihypertensive treatment 1731
nephropathy is due to a hemodynamic effect, which does not
attenuate over time. The subsequent slower decline in GFR
reflects the beneficial effect of antihypertensive treatment on the
progression of diabetic nephropathy.
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